

14 June 2022

ASX Announcement

AdAlta granted European patent protecting AD-214

MELBOURNE Australia, 14 June 2022: AdAlta Limited (ASX:1AD), the clinical stage biotechnology company developing novel therapeutic products from its i-body platform, is pleased to announce that its first European patent relating to lead program, AD-214, has been granted by the European Patent Office.

Patent Number EP3242685, entitled “CXCR4 binding molecules”, has an expiry date of 8 January 2036.

AdAlta’s CEO and Managing Director, Dr Tim Oldham said:

“Grant of this European patent means AD-214 now has patent protection until 2036 in the eight largest pharmaceutical markets in the world: US, Japan, China, Germany, France, Italy, Spain and UK.”

The new patent protects the i-body sequence used in AdAlta’s lead product, AD-214, sequences similar to this, and pharmaceutical compositions and derivatives containing these i-body sequences. The patent also protects the use of these sequences in therapeutic and diagnostic applications, including Idiopathic Pulmonary Fibrosis (IPF), the lead indication for which AD-214 is being developed.

AdAlta is now taking the steps necessary to validate this patent in 18 countries across Europe. Validation is an administrative process necessary to enable the patent to be enforced in each country. Validation is anticipated to be complete by August 2022.

This European Patent adds to existing patent protection for AD-214 in Australia (two patents), China, India, Japan, Singapore and US (two patents).

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
June 2022

Notes to Editors

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need. AdAlta has a second target in discovery research, also in the field of fibrosis and inflammation.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies (i-CAR-T) to bring new hope to patients with cancer. It has an agreement with GE Healthcare to co-develop i-bodies as diagnostic imaging agents (i-PET imaging) against Granzyme B, a biomarker of response to immuno-oncology drugs, a program now in preclinical development.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: <https://adalta.com.au>

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 117 774
E: jane.lowe@irdepartment.com.au